Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02107131 · ClinicalTrials.gov registry record · Phase 4
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
A Phase 4 study of Diabetic Macular Edema, sponsored by California Retina Consultants.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT02107131 is a Phase 4 study of Diabetic Macular Edema that has completed, run by California Retina Consultants. The registered enrollment target is 40 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT02107131, a Phase 4 study of Diabetic Macular Edema, has completed, sponsored by California Retina Consultants.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).
Conditions Studied
Interventions
- DRUG Intravitreal ranibizumab 0.3mg
Study Locations (6)
California
- California Retina Consultants - Bakersfield - Bakersfield
- California Retina Consultants - Oxnard
- California Retina Consultants - Palmdale
- California Retina Consultants - Santa Barbara Office - Santa Barbara
- California Retina Consultants - Santa Maria
- California Retina Consultants - Visalia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-03-13 |
| Est. Completion | 2017-05-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02107131
The ClinicalTrials.gov registry entry for NCT02107131 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is California Retina Consultants, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Intravitreal ranibizumab 0.3mg is the first listed.
NCT02107131 reports 6 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02107131 about?
NCT02107131 is a clinical study titled "Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab". Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).
What is the current status of trial NCT02107131?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-03-13. Estimated completion is 2017-05-15.
What conditions does trial NCT02107131 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT02107131?
The interventions under investigation include: Intravitreal ranibizumab 0.3mg (DRUG).
Who is sponsoring clinical trial NCT02107131?
This trial is sponsored by California Retina Consultants, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02107131 being conducted?
This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 4
-
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 4
-
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
ACTIVE NOT RECRUITING · Phase 4
-
Ocular Safety and Usability Study for FYB203 PFS
COMPLETED · Phase 4
-
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
COMPLETED · Phase 4
-
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.